TickerTalks
Browse all tickers →
TickerTalks›$RGC
RGRGC

Regencell Bioscience Holdings Limited

$RGC·$3.1B·Drug Manufacturers - Specialty & Generic·Healthcare
$6.22+0.3%YTD-71.9%1Y-59.7%
Price updated 15h ago·X counts updated 4d ago
RGRGC
$RGCRegencell Bioscience Holdings Limited
$6.22+0.32%13 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $RGC on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

13X posts · last 7 days
Sep 13Sep 27
Mixed sentimentAI analysisGenerated by AI from underlying data6 posts analyzed · as of 2026-07-14

$RGC chatter is split between bulls building a squeeze thesis—zero shares available to borrow, 255% short-borrow fee, CEO owning nearly 90% of shares locked up, recent offering closing above $20, and $10 flagged as the parabolic trigger—and a bear victory lap noting the stock is now trading at $5.25 after $70+ callouts, with commentators who shorted still up more than 1300%.

Read what X is saying about $RGC

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $RGC — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-10-01

Falling on heavy selling — points lower unless it turns around.

TCM pharma microcap $3.1B down 72% YTD at 2.7% of 52-week range, 255% borrow fee, split sentiment

Regencell Bioscience is a $3.1B traditional-Chinese-medicine microcap at 2.7% of its 52-week range after a 72% year-to-date decline — the equity has one of the most contested float-and-short setups in the market, with a 255% borrow fee and the CEO owning near 90% of shares.

  • 2025 full-year revenue zero, operating margin not applicable, EPS -$0.0107; the entity is pre-revenue by any meaningful definition — the market cap is purely narrative-and-float
  • No consensus estimates visible; the market cap is a function of CEO ownership + a tiny public float (hence the 255% borrow fee)
  • 52-week range position 2.7%, trading +7.6% above the 50-day — a technical bounce inside a brutal trailing twelve-month drawdown; beta 1.43

Oct 28 earnings is the next scheduled event; the equity trades on squeeze mechanics plus the perceived value of the TCM-development pipeline, not fundamentals. The bear case ('shorted and still +1300%') is the honest counter to the squeeze thesis.

Agrees with X sentimentX is split — bulls build a squeeze thesis on the 255% borrow fee, zero shares available to borrow, CEO owning ~90% of shares locked up, recent offering closing above $20, and $10 as the parabolic trigger. Bears take a victory lap at $5.25 after $70+ callouts, with commentators who shorted still +1300%. Both sides read the data correctly; the equity is a float-and-short mechanics bet, not a fundamentals investment.

What to watch: Oct 28 earnings — any revenue update (any at all), cash runway, borrow-fee dynamics, and the squeeze trigger at $10 if volume ever shifts.

On the calendar: 2026-10-28 — Fiscal 2026 earnings

Read the AI verdict on $RGC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Biotech developing Traditional Chinese Medicine therapies targeting ADHD and neurocognitive disorders.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $RGC.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

What this means for $RGC

Neutral — Biotech developing Traditional Chinese Medicine therapies targeting ADHD and neurocognitive disorders.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+18.2%YTD
+38.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-602.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-444%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
0.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-232%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Jun 15, 2026$-0.01——
Q3 2025Nov 18, 2025$-0.00——
Q1 2025Jun 26, 2025$-0.14——
Q3 2024Oct 25, 2024$-0.00——
Next earningsWed, Oct 28

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.01—
Q4 FY25$0———$-0.00$0
Q2 FY25$0———$-0.00$0
Q4 FY24$0-100.0%——$-0.00$-2.0M

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.3%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-67.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 17.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.435-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 2 other (2 returns) in window

See when $RGC insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)May 19424B5
AI summary

Regencell Bioscience Holdings (RGC) filed a 424B5 prospectus supplement on May 19, 2026 for a registered direct offering of 985,222 ordinary shares at $20.30/share — a ~27% discount to the prior close of $27.79 — raising $20.0M gross ($18.7M net after $1.3M placement agent fees). Univest Securities acted as placement agent and also purchased 49,262 shares as principal for $1M of its own account. Immediate dilutive offering at a steep discount — material capital structure event for this small-cap biotech.

+ 5 other (5 6-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

RGC Resources, Inc. Declares Quarterly Dividendglobenewswire.com·3d agoRGC Resources: More Likely To Appeal More To Income-Focused Investorsseekingalpha.com·44d agoRGC Resources Q3 Earnings Call Highlightsmarketbeat.com·55d agoRGC Resources, Inc. Reports Third Quarter Earningsglobenewswire.com·57d agoUnited Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promisesseekingalpha.com·87d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$EVO$TEVA$ZTS$INDV$ACB$ELAN$CRON$ETON
Voices on X · last 7 days

No standout posts about $RGC on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport